U.S. health authorities are signing off on human trials of CBD to treat opioid addiction. The U.S. Food and Drug Administration gave the green light this week to Ananda Scientific to start human testing of its CBD drug Nantheia ATL5, the company announced. The trials will be run out of UCLA and are funded by